Malicious sites use JavaScript to build malware in browser memory

A massive malvertising campaign is using fake Solana, Luno, and TradingView webpages with malicious JavaScript that instructs ...
Microsoft

Unpacking the AsyncAPI npm supply chain compromise and import-time payload delivery

Threat actors compromised AsyncAPI packages and weaponized trusted CI/CD workflows to distribute malware through npm. This ...

AsyncAPI npm packages infected with credential-stealing malware

Five malicious versions of AsyncAPI packages were published to the Node Package Manager (npm) in a supply-chain attack that ...
Computerworld

How to use Excel formulas and functions

Formulas are powerful tools for performing calculations and analyzing data in Excel. In this beginner’s guide, you’ll learn how to use formulas (with or without help from the Copilot AI assistant) and ...
Hacker

Interactive Data Chart Generator (Pure JavaScript Canvas Tool)

I'm an independent creator passionate about building useful tools, simulations, and theories that make complex ideas more accessible. I explore the intersection of technology, education, and human ...
Forbes

Generate Biomedicines IPO Turns Heads

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...
Reuters

Generate Biomedicines shares fall in weak Nasdaq debut for drug developer

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...
FierceBiotech

Behind Generate's 'feverish' race to raise $400M IPO while window remains open

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...
Reuters

Drug developer Generate Biomedicines raises $400 million in US IPO

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...
The Boston Globe

Flagship-backed Generate Biomedicines seeks $425 million in IPO

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...
Seeking Alpha

Generate Biomedicines Begins IPO Push With Major Collaboration Deals

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...
The Washington Post

X responds to outcry over Grok’s sexual images by charging users to create them

Grok, the AI chatbot on Elon Musk’s social media platform X, is limiting image generation and editing capabilities to paying subscribers amid a global outcry from officials and users over the tool ...